IS5864A - Ný hýdratform af alendrónatnatríum, aðferðir við framleiðslu þeirra og lyfjablöndur þeirra - Google Patents

Ný hýdratform af alendrónatnatríum, aðferðir við framleiðslu þeirra og lyfjablöndur þeirra

Info

Publication number
IS5864A
IS5864A IS5864A IS5864A IS5864A IS 5864 A IS5864 A IS 5864A IS 5864 A IS5864 A IS 5864A IS 5864 A IS5864 A IS 5864A IS 5864 A IS5864 A IS 5864A
Authority
IS
Iceland
Prior art keywords
new
alendronate sodium
manufacturing
methods
pharmaceutical formulations
Prior art date
Application number
IS5864A
Other languages
English (en)
Inventor
Finkelstein Nina
Lidor-Hadas Ramy
Aronhime Judith
Original Assignee
Teva Pharmaceutical Industries Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Teva Pharmaceutical Industries Ltd filed Critical Teva Pharmaceutical Industries Ltd
Publication of IS5864A publication Critical patent/IS5864A/is

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/28—Phosphorus compounds with one or more P—C bonds
    • C07F9/38—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/28—Phosphorus compounds with one or more P—C bonds
    • C07F9/38—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
    • C07F9/3804—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)] not used, see subgroups
    • C07F9/3839—Polyphosphonic acids
    • C07F9/3873—Polyphosphonic acids containing nitrogen substituent, e.g. N.....H or N-hydrocarbon group which can be substituted by halogen or nitro(so), N.....O, N.....S, N.....C(=X)- (X =O, S), N.....N, N...C(=X)...N (X =O, S)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Rheumatology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
IS5864A 1998-08-27 2001-02-26 Ný hýdratform af alendrónatnatríum, aðferðir við framleiðslu þeirra og lyfjablöndur þeirra IS5864A (is)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US9831398P 1998-08-27 1998-08-27
US12974399P 1999-04-16 1999-04-16
US14446199P 1999-07-19 1999-07-19
PCT/US1999/019838 WO2000012517A1 (en) 1998-08-27 1999-08-27 Novel hydrate forms of alendronate sodium, processes for manufacture thereof, and pharmaceutical compositions thereof

Publications (1)

Publication Number Publication Date
IS5864A true IS5864A (is) 2001-02-26

Family

ID=27378576

Family Applications (1)

Application Number Title Priority Date Filing Date
IS5864A IS5864A (is) 1998-08-27 2001-02-26 Ný hýdratform af alendrónatnatríum, aðferðir við framleiðslu þeirra og lyfjablöndur þeirra

Country Status (30)

Country Link
US (2) US6281381B1 (is)
EP (1) EP1107974B1 (is)
JP (2) JP2002523514A (is)
KR (2) KR20070034132A (is)
AT (1) ATE334993T1 (is)
AU (1) AU5698899A (is)
BG (1) BG65329B1 (is)
BR (1) BR9913472A (is)
CA (1) CA2341459A1 (is)
CZ (1) CZ2001629A3 (is)
DE (1) DE69932620T2 (is)
DK (1) DK1107974T3 (is)
EA (1) EA002739B1 (is)
EE (1) EE04552B1 (is)
ES (1) ES2270613T3 (is)
HR (1) HRP20010129A2 (is)
HU (1) HUP0203078A3 (is)
IL (1) IL141423A (is)
IS (1) IS5864A (is)
LT (1) LT4888B (is)
LV (1) LV12720B (is)
NO (1) NO20010957L (is)
NZ (1) NZ510682A (is)
PL (1) PL346347A1 (is)
PT (1) PT1107974E (is)
RO (1) RO122854B1 (is)
SI (1) SI20581B (is)
SK (1) SK2482001A3 (is)
WO (1) WO2000012517A1 (is)
YU (1) YU14701A (is)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60235085D1 (de) * 2001-07-16 2010-03-04 Univ Paris Xiii Herstellungsverfahren von derivate von bisphosphonaten
GB2383042A (en) * 2001-10-18 2003-06-18 Cipla Ltd Amorphous alendronate sodium
BR0215413A (pt) * 2001-12-24 2004-12-14 Teva Pharma Formula dosada com um comprimido central de ingrediente ativo encapado em uma capa anular prensada de material em pó ou granulado e processo e conjunto de ferramentas para a sua produção
US20040052843A1 (en) * 2001-12-24 2004-03-18 Lerner E. Itzhak Controlled release dosage forms
ITMI20020146A1 (it) * 2002-01-29 2003-07-29 Lyogen Ltd Alendronato monosodico amorfo e processo per la sua preparazione
AU2003226148A1 (en) * 2002-04-05 2003-10-27 Merck & Co., Inc. Method for inhibiting bone resorption with an alendronate and vitamin d formulation
US20080249068A1 (en) * 2002-09-05 2008-10-09 Deluca Hector F Method of Extending the Dose Range of Vitamin D Compounds
US20050113343A1 (en) * 2003-10-14 2005-05-26 Pliva - Research And Development Ltd. Solid-state form of alendronate sodium and preparation thereof
US20050181043A1 (en) * 2004-02-12 2005-08-18 Indranil Nandi Alendronate salt tablet compositions
US20050261250A1 (en) * 2004-05-19 2005-11-24 Merck & Co., Inc., Compositions and methods for inhibiting bone resorption
WO2005115331A2 (en) 2004-05-24 2005-12-08 The Procter & Gamble Company Enteric solid oral dosage form of bisphosphonate containing a chelating agent
CZ296937B6 (cs) * 2004-09-02 2006-07-12 Zentiva, A. S Trisodná sul kyseliny 4-amino-1-hydroxybutyliden-1,1-bisfosfonové
AR052321A1 (es) * 2004-10-29 2007-03-14 Sandoz Ag Procesos para la preparacion de un polipeptido
US20060134190A1 (en) * 2004-12-16 2006-06-22 Banner Pharmacaps Inc. Formulations of bisphosphonate drugs with improved bioavailability
CZ297262B6 (cs) * 2004-12-28 2006-10-11 Zentiva, A. S. Trisodná sul kyseliny 4-amino-1-hydroxybutyliden-1,1-bisfosfonové
US8003820B2 (en) * 2005-10-20 2011-08-23 Dr. Reddy's Laboratories Limited Process for preparing bisphosphonic acids
AR058168A1 (es) * 2005-11-07 2008-01-23 Merck & Co Inc Sintesis del alendronato de sodio trihidratado
MX2009003913A (es) * 2006-10-27 2009-04-24 Signal Pharm Llc Formas solidas que comprenden 4-[9-(tetrahidro-furano-3-il)-8-(2,4 ,6-trifluoro-fenilamino)-9h-purin-2-ilamino]-ciclohexan-1-ol, composiciones de las mismas, y su uso.
JP5244608B2 (ja) * 2006-11-22 2013-07-24 エーザイ・アール・アンド・ディー・マネジメント株式会社 二糖類化合物のナトリウム塩及びその製造方法並びにその使用
US20090118238A1 (en) * 2007-09-17 2009-05-07 Protia, Llc Deuterium-enriched alendronate
US20090076144A1 (en) * 2007-09-17 2009-03-19 Protia, Llc Deuterium-enriched bazedoxifene
US20090170815A1 (en) * 2007-12-28 2009-07-02 Roxane Laboratories Incorporated. Alendronate oral liquid formulations
CN102040644B (zh) * 2009-11-03 2014-05-14 刘力 丹参酮衍生物及其制备和用途
RU2021125455A (ru) 2013-11-15 2021-10-05 Экебиа Терапьютикс, Инк. Твердые формы { [5-(3-хлорфенил)-3-гидроксипиридин-2-карбонил]амино} уксусной кислоты, их композиции и применения

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3016289A1 (de) 1980-04-28 1981-10-29 Henkel KGaA, 4000 Düsseldorf Verfahren zur herstellung von omega -amino-1-hydroxyalkyliden-1,1-bis-phosphonsaeuren
IT1201087B (it) 1982-04-15 1989-01-27 Gentili Ist Spa Bifosfonati farmacologicamente attivi,procedimento per la loro preparazione e relative composizioni farmaceutiche
US4639338A (en) * 1984-08-06 1987-01-27 Ciba-Geigy Corporation Preparation of crystalline disodium 3-amino-1-hydroxypropane-1,1-diphosphonate pentahydrate
DE3434667A1 (de) 1984-09-21 1986-04-03 Henkel KGaA, 4000 Düsseldorf 4-dimethylamino-1-hydroxybutan-1,1-diphosphonsaeure, deren wasserloesliche salze, verfahren zu ihrer herstellung sowie ihre verwendung
IT1196315B (it) * 1984-10-29 1988-11-16 Gentili Ist Spa Procedimento per la preparazione di acidi difosfonici
US4711800A (en) * 1985-06-06 1987-12-08 Divincenzo Maureen Needlecraft with metallic substrate
US4922007A (en) * 1989-06-09 1990-05-01 Merck & Co., Inc. Process for preparing 4-amino-1-hydroxybutylidene-1,1-bisphosphonic acid or salts thereof
US5019651A (en) * 1990-06-20 1991-05-28 Merck & Co., Inc. Process for preparing 4-amino-1-hydroxybutylidene-1,1-bisphosphonic acid (ABP) or salts thereof
US5039819A (en) 1990-09-18 1991-08-13 Merck & Co., Inc. Diphosphonate intermediate for preparing an antihypercalcemic agent
US5159108A (en) * 1990-09-18 1992-10-27 Merck & Co., Inc. Process for preparing an antihypercalcemic agent
AU6148396A (en) * 1995-06-06 1996-12-24 Merck & Co., Inc. Disodium alendronate formulations
DE69634357T2 (de) * 1995-06-06 2006-01-12 Merck & Co., Inc. Formulierungen mit dem wasserfreien mononatriumsalz von alendronat und deren verwendung zur behandlung von knochenkrankheiten

Also Published As

Publication number Publication date
IL141423A (en) 2005-09-25
NO20010957L (no) 2001-04-26
EP1107974B1 (en) 2006-08-02
AU5698899A (en) 2000-03-21
SI20581A (sl) 2001-12-31
SK2482001A3 (en) 2002-01-07
EE200100126A (et) 2002-06-17
ES2270613T3 (es) 2007-04-01
HUP0203078A3 (en) 2005-01-28
KR20070034132A (ko) 2007-03-27
HUP0203078A2 (hu) 2003-01-28
EA200100184A1 (ru) 2001-10-22
IL141423A0 (en) 2002-03-10
WO2000012517A1 (en) 2000-03-09
HRP20010129A2 (en) 2005-04-30
EA002739B1 (ru) 2002-08-29
EP1107974A4 (en) 2001-09-26
DE69932620T2 (de) 2006-12-14
ATE334993T1 (de) 2006-08-15
LV12720A (lv) 2001-09-20
WO2000012517A9 (en) 2000-07-13
DK1107974T3 (da) 2006-10-30
US6696601B2 (en) 2004-02-24
LT4888B (lt) 2002-02-25
LT2001016A (en) 2001-10-25
BG105292A (en) 2001-12-29
DE69932620D1 (de) 2006-09-14
SI20581B (sl) 2008-06-30
CZ2001629A3 (cs) 2001-08-15
RO122854B1 (ro) 2010-03-30
US20030065214A1 (en) 2003-04-03
NO20010957D0 (no) 2001-02-26
BG65329B1 (bg) 2008-02-29
PL346347A1 (en) 2002-02-11
LV12720B (en) 2002-02-20
BR9913472A (pt) 2002-03-05
JP2009143955A (ja) 2009-07-02
YU14701A (sh) 2003-01-31
EP1107974A1 (en) 2001-06-20
CA2341459A1 (en) 2000-03-09
PT1107974E (pt) 2006-10-31
JP2002523514A (ja) 2002-07-30
US6281381B1 (en) 2001-08-28
EE04552B1 (et) 2005-10-17
NZ510682A (en) 2003-09-26
KR20010079701A (ko) 2001-08-22

Similar Documents

Publication Publication Date Title
IS5864A (is) Ný hýdratform af alendrónatnatríum, aðferðir við framleiðslu þeirra og lyfjablöndur þeirra
CY1107927T1 (el) Ενωσεις φωσφονικου
NO952863D0 (no) Fluoxetin-farmasöytiske sammensetninger
AU7642001A (en) Novel $G(Y) crystalline form of perindopril tert-butylamine salt, preparation method, and pharmaceutical compositions containing same.
HUP0400781A3 (en) Process for the crystallization of (r)- or (s)-lansoprazole, the prepared crystalls and pharmaceutical compositions containing them and their use
NO20050664L (no) 2,4 substituerte indoler og anvendelse derav som 5-HT6 modulatorer
DE60120691D1 (de) Zusammensetzungen zur verwendung bei der behandlung der osteoporose und/oder der entzündlichen gelenkerkrankungen
NO20030050L (no) Ny <beta>-krystallinsk form av perindopril tert- butylaminsalt, fremgangsmåte for dens fremstilling og farmasöytiske sammensetningerinneholdende den
HUP0401141A3 (en) Crystalline forms of fluvastatin sodium, process for their preparation and pharmaceutical compositions containing them
PT1051159E (pt) Composicoes farmaceuticas solidas contendo miltefosina para administracao oral no tratamento de leishmaniose
ATE266029T1 (de) Substituierte pyrrolobenzimidazolderivate zur entzündungshemmung
MXPA04005809A (es) Inhibidores de proteinas quinasas.
TR200200278T2 (tr) Kalsilitik bileşimler
DE69939559D1 (de) Methode zur Beschleunigung der Schleimauflöserate
EP1702924A3 (en) Novel hydrate forms of alendronate sodium, processes for manufacture thereof, and pharmaceutical compositions thereof
BR9714973A (pt) Formulações de goma de mascar incluindo aspartame e bicarbonato de sódio
CR20120385A (es) Nuevos pirrolocarbazoles fusionados (divisional exp. 8519)
ITMI981691A1 (it) Composizioni farmaceutiche atte alla sommistrazione per via transdermale di apomorfina
MY118194A (en) Pharmaceutical compositions for use in inhibiting bone resorption